Breaking News, Collaborations & Alliances

CBM, Virion Partner on CD8+ T cell-based Clinical Development Programs

CBM will manufacture and partner with Virion on their checkpoint modifier clinical development programs, including the First-in-Human VRON-0200 immunotherapy.

Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing critical challenges associated with the commercialization of cell and gene therapies, and Virion Therapeutics (Virion), a clinical-stage biotech company focused on the development of accessible CD8+ T cell-based technologies for cancers and infectious diseases, entered a strategic collaboration agreement wherein CBM will manufacture and partner with Virion on their checkp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters